TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05673941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative physical training
Description: The intervention will be performed as a group activity twice a week during a 12-week period. Each group will include 4-6 participants under the guidance of two instructors, and a related party if needed or wanted from the participant. The exercise is partly accompanied with calm music and recorded nature sounds and partly made in silence listening to one's own bodily rhythm. The exercise consists of tasks related to cardio and strength training, balance, conscious breathing, body awareness, mental imagery (nature visualizations), flexibility, emotional expression, and movement anticipation together with the facilitator and fellow participants. All the tasks are practiced during a flow of 45- to 60-minute exercise without any major breaks. Complexity and physical intensity of the tasks will gradually increase over the 12-week intervention period.
Study: NCT05352581

Intervention type: DIAGNOSTIC_TEST
Intervention: BD Veritor At-Home
Description: BD Veritor At-Home rapid self testing

Intervention type: DIAGNOSTIC_TEST
Intervention: BD Veritor Professional
Description: BD Veritor Professional rapid test
Study: NCT05512741

Intervention type: OTHER
Intervention: Feces collection
Description: Feces will be collected, at home, by the patient., by using a collection kit. The stools are collected in the 2 last days before surgery.~After surgery, the first stool is collected, during the hospitalization, by using the same kit. Stools are conserved in the same condition, before being frozen in our local biologic ressources center.

Intervention type: OTHER
Intervention: Feces collection
Description: Feces will be collected, at home, by the patient., by using a collection kit. The stools are collected in the 2 last days before surgery.~After surgery, the first stool is collected, during the hospitalization, by using the same kit. Stools are conserved in the same condition, before being frozen in our local biologic ressources center.
Study: NCT06349759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
Description: Once daily dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily dosing
Study: NCT05870696

Intervention type: DIAGNOSTIC_TEST
Intervention: PrecogColo Dx test
Description: the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer

Intervention type: DIAGNOSTIC_TEST
Intervention: PrecogColo Dx test
Description: the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer
Study: NCT06132139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisAR
Description: The study device is a Microsoft HoloLens which uses Novarad's proprietary software and is collectively known as VisAR.
Study: NCT04677413

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrafractionated radiotherapy for rectal cancer
Description: To determine the toxicity of dose-escalated hypofractionated RT, in patients with locally advanced rectal cancer treated with RT, FOLFOX or CAPOX chemotherapy and selective omission of surgery.
Study: NCT05083832

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Erector Spina Plane Block vs Continuous Serratus Anterior Plane Block
Description: Two different catheter techniques with same doses local anesthetic infusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Erector Spina Plane Block vs Continuous Serratus Anterior Plane Block
Description: Two different catheter techniques with same doses local anesthetic infusion
Study: NCT05525806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Materials for MyProstateScore
Description: These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Materials for MyProstateScore
Description: These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
Study: NCT06109818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-488 Tablets
Description: ICP-488 will be administered as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-488 Tablets
Description: ICP-488 will be administered as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-488 Placebo
Description: ICP-488 Placebo will be administered as tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICP-488 Placebo
Description: ICP-488 Placebo will be administered as tablet
Study: NCT06148324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MENTOR Program
Description: MENTOR is an online wellness program covering 11 wellness modules: Exercise; Nutrition; Mindfulness; Spiritual Practice; Self-Care; Arts \& Leisure; Rest \& Relaxation; Outdoors in Nature; Relationships; Core Values; and Contribution to Others.~The 8-week cycle comprises 40 hours of online group-based instruction and discussion, meeting up to five times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MENTOR Program
Description: MENTOR is an online wellness program covering 11 wellness modules: Exercise; Nutrition; Mindfulness; Spiritual Practice; Self-Care; Arts \& Leisure; Rest \& Relaxation; Outdoors in Nature; Relationships; Core Values; and Contribution to Others.~The 8-week cycle comprises 40 hours of online group-based instruction and discussion, meeting up to five times per week.
Study: NCT06092268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009 for injection ； Almonertinib Mesilate Tablets
Description: Phase IB: SHR-A2009 will be administered intravenously，Almonertinib Mesilate Tablets will be administered orally. 2 or 3 dose levels are preset in phase IB.~Phase II: 2 dose cohorts will be selected and it's randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009 for injection；Adebrelimab Injection
Description: Phase IB: SHR-A2009 and Adebrelimab will be administered intravenously. 2 dose levels are preset in phase IB.~Phase II: RPD2 will be selected to evaluate preliminary efficacy.
Study: NCT06164639

Intervention type: BEHAVIORAL
Intervention: aspiration
Description: Based on whether the patient meets the diagnosis of aspiration pneumonia.

Intervention type: DIAGNOSTIC_TEST
Intervention: bronchial alveolar fluid
Description: Performing bronchoscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: bronchial alveolar fluid
Description: Performing bronchoscopy.
Study: NCT05283512

Intervention type: OTHER
Group type: OTHER
Intervention: Preventive treatment with IV-hydration
Description: IV hydration with isotonic 0.9% NaCl

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preventive treatment with oral hydration
Description: Oral hydration with regular bottled water
Study: NCT05236088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation application
Description: It was applied with INNOVO brand (Atlantic Therapeutics, Galway, Ireland) device. It was applied for 30 minutes 3 days a week during 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham neuromuscular electrical stimulation application
Description: Sham group will be applied from the same device, again 3 days a week for 30 minutes during 4 weeks, but no current will be given from the device.
Study: NCT05448443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD981
Description: Oral administration of AD981 in the morning and before sleep for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo in the morning and before sleep for 14 days
Study: NCT05256498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picostim Amber
Description: Picostim Amber temporary (24h) lead placement and extracorporeal stimulation
Study: NCT05236699

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DEB-TACE combined with Surufatinib and Camrelizumab
Description: 1. All patients will be treated with standard DEB-TACE on the first day (D1).~2. After DEB-TACE, if the liver function is Child-PughA grade, they will be treated with Camrelizumab on the same day, 200mg/ times, intravenous injection, once every 3 weeks.~3. Surufatinib capsule will be given orally to 250mg within 1 hour after breakfast on the second day (D2) after the first DEB-TACE. The drug will be given continuously once a day and stopped on the same day of each DEB-TACE.~4. The combination of drugs for 3 weeks is a cycle.The treatment will continue until the patient developed the disease or met the other criteria for terminating the study.
Study: NCT06517030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Extraction
Description: After local anaesthesia, a buccal split-full-split-thickness envelope flap will be elevated, and the tooth will be extracted a-traumatically.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Extraction
Description: After local anaesthesia, a buccal split-full-split-thickness envelope flap will be elevated, and the tooth will be extracted a-traumatically.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Implant Placement
Description: After providing that the extraction socket will meet the inclusion criteria, an implant will be immediately inserted with 1 mm of its transmucosal portion positioned under the interproximal bone crest.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Implant Placement
Description: After providing that the extraction socket will meet the inclusion criteria, an implant will be immediately inserted with 1 mm of its transmucosal portion positioned under the interproximal bone crest.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket reconstruction with DBBB+HA
Description: The gap between the implant surface and the bone plates will be filled with deproteinized bovine bone mineral with hyaluronic acid (DBBM+HA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket reconstruction with DBBB
Description: The gap between the implant surface and the bone plates will be filled with deproteinized bovine bone mineral (DBBM).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG placement
Description: Once the appropriate healing abutments will be installed, a CTG will be utilized as a barrier membrane. Then, the buccal flap will be coronally advanced and will be adapted to the healing abutment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTG placement
Description: Once the appropriate healing abutments will be installed, a CTG will be utilized as a barrier membrane. Then, the buccal flap will be coronally advanced and will be adapted to the healing abutment.
Study: NCT05927337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for managing Obesity
Description: Patients included in the intervention group will be treated with a tailored cognitive behavioural therapy programme for obesity management. The programme is designed and adapted from the Individualised Cognitive Behavioural Therapy for Obesity Management programme (Dalle Grave et al., 2018), which is divided into six content modules aimed at weight loss and weight maintenance. For the purpose of the research, an abbreviated programme will be designed and used, and the content modules will remain the same as in the original version of the programme.
Study: NCT06153719

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 12-weeks combined exercise intervention
Description: This 12-week combined exercise intervention will consist of 3 supervised exercise classes per week, each one lasting 50 minutes. It will involve both aerobic and resistance training in order to follow the UK's physical activity recommendations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-weeks combined exercise intervention
Description: This 12-week combined exercise intervention will consist of 3 supervised exercise classes per week, each one lasting 50 minutes. It will involve both aerobic and resistance training in order to follow the UK's physical activity recommendations
Study: NCT05928546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: Intra-pocket application of quercetin nanoemulgel :~* After conventional periodontal treatment, the teeth were isolated by cotton rolls for intra pocket application of the gel.~* That gel was injected in periodontal pocket using syringe with blunt cannula till the gel excess exit from the pocket .

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: scaling and root planing
Description: - Full-mouth scaling and root planing was performed in 1-2 sessions within 2 weeks using manual scalers and curettes or ultrasonic scaler and local anesthesia was used in case of need for patient comfort.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Description: - Full-mouth scaling and root planing was performed in 1-2 sessions within 2 weeks using manual scalers and curettes or ultrasonic scaler and local anesthesia was used in case of need for patient comfort.
Study: NCT06120829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Description: Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Description: Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core Needle Biopsy
Description: Core Needle Biopsy
Study: NCT05262829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Mesenchymal Stem Cells
Description: MSCs treatment by intestinal submucosal injection/MSCs treatment by intravenous drip + MSCs treatment by intestinal submucosal injection
Study: NCT05740878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: immunonutrients oral nutritional supplements
Description: 1 serving of ONS immunonutrients which is 57 grams of ready-to-brew powder yields 200 ml of a liquid formula containing 251 kcal energy (1.26 kcal/ml), 9 grams protein (14%), 94 mg omega-3, and 20 mg anthocyanins.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard oral nutritional supplements
Description: 1 serving of standard ONS which is 57 grams of ready-to-brew powder yields 200 ml of liquid formula containing 258 kcal energy (1.26 kcal/ml), 5 g (7.5%) protein , 7 g (24%) fat, 43 g (68%) carbohydrate
Study: NCT04655937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: 9 x two hour remote sessions (50 minutes activity + 20 minute break + 50 minutes activity). Acceptance and Commitment Therapy (ACT) is a third wave transdiagnostic cognitive-behavioural therapy that supports clients to adjust to current experiences and 'commit' to behaviours that are congruent with their personal values, in order to promote psychological well-being and prevent future mental health crisis. ACT uses a variety of experiential techniques to support this process including: mindfulness practices; exercises to identify personal values; commitment to goals for valued living.
Study: NCT05539300

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-PET/CT response evaluation
Description: PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront enzalutamide therapy
Study: NCT04985552

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP Breast Reconstruction
Description: All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice: 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIEP Breast Reconstruction
Description: All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice: 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ciNPT
Description: Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system \[V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)\] applied by the operating surgeon in a sterile fashion. The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Tape Dressings
Description: Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
Study: NCT05622253

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser
Description: Selected patients will be treated with low-dose oral isotretinoin (10mg/day) over a period of sessions and six sessions of 1064 ND- YAG laser (Deka motous AY) using 150 J/cm2, 20-25 milliseconds pulse duration, and 5 mm spot size, at 2 weeks' interval.
Study: NCT04802668

Intervention type: DEVICE
Intervention: Patients were ventilated with assist-control ventilation（A/C） mode at different tidal volume
Description: Ventilation mode was set to assist-control volume ventilation with different tidal volume, respiratory frequency 15 times/min, PEEP 5 centimeter water column.

Intervention type: BEHAVIORAL
Intervention: spontaneous breathing and no spontaneous breathing
Description: Data were recorded when patients had and did not have spontaneous breathing
Study: NCT06092814

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active transcranial alternating current stimulation (tACS)
Description: Transcranial Alternating Current Stimulation (tACS) is a device that applies a low-intensity electrical current to the brain through electrodes on the scalp.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Active transcranial alternating current stimulation (tACS)
Description: Transcranial Alternating Current Stimulation (tACS) is a device that applies a low-intensity electrical current to the brain through electrodes on the scalp.
Study: NCT05330247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein (CRHP) Diet
Description: Macronutrient intake of 30 percentage of energy from carbohydrate, 30 percentage of energy from protein and 40 percentage of energy from fat.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional diabetes (CD) Diet
Description: Macronutrient intake of 50 percentage of energy from carbohydrate, 17 percentage of energy from protein and 33 percentage of energy from fat.
Study: NCT05902052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Protocol
Description: Evaluation of patients' pain in the extubated period with the Visual Anolog Scale Active participation of the patient in pain reporting Regular questioning of the patient's pain Questioning pain at rest and movement Implementing nursing interventions in painful condition (VAS≤ 4)
Study: NCT06226857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: FOLFOX+cetuximab/panitumumab q2w until desease progression, deescalation to de Gramont+cetuximab/panitumumab is allowed after 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: FOLFOX+cetuximab/panitumumab q2w until desease progression, deescalation to de Gramont+cetuximab/panitumumab is allowed after 8 cycles
Study: NCT06522594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: A vey cardioselective, short-acting betablocker, with an ultra-short half life time.
Study: NCT06436677

Intervention type: OTHER
Intervention: molecular subtype based treatment
Description: The immunohistochemistry algorithm established by the previous research group was used to determine the molecular subtype, and the corresponding treatment plan was selected according to the subtype. Such as for TCyEM patients, interferon-based immunomodulatory therapy was selected, and TCM-type patients were treated with retinoids.
Study: NCT05666050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health intervention
Description: Pregnant women with 26-28 weeks of gestation(based on world health organization eligibility criteria) will be recruited and baseline data will be collected at selected clusters. Women who will provide informed consent will be asked to complete a post-consent eligibility assessment including access to a mobile phone, and willingness to receive health messages on their mobile phone. Women who meet these eligibility criteria will be enrolled in the study and administered the baseline interview. Intervention will be started among randomly selected clustered pregnant women at 30 weeks of gestation and will be continued up to 6 weeks of post partum period for 4 months.